AWM
PHAS

Accel Wealth Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Accel Wealth Management’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-100
Closed – – 907
2020
Q4 		$0 Buy
+100
New +$358 ﹤0.01% 845

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM

Accel Wealth Management's PHAS Position: Q1 2021 in Review

Accel Wealth Management sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q1 2021, closing a stake of 100 shares.

Accel Wealth Management first reported a position in PHAS in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 61 funds tracked by Wall St. Rank hold PHAS as of Q1 2021.

  • Accel Wealth Management reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Accel Wealth Management sold 100 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q1 2021.
  • Accel Wealth Management first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Accel Wealth Management's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $0 in Q4 2020.
  • 61 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q1 2021.

Based on Accel Wealth Management's 13F filing for Q1 2021, filed 10 May 2021.